LENZ News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

LE

Mkt Cap

$102.7M

Volume

820.39K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZPomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance.GlobeNewswire Inc. · Oct 6, 2026

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater ChinaLENZ Therapeutics announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100) in Greater China through an Asset Purchase Agreement with Corxel Pharmaceuticals. The New Drug Application for LNZ100 was submitted to China's NMPA in September 2025 with approval anticipated in Q1 2027. LENZ is eligible to receive up to $85 million in regulatory and sales milestones plus tiered royalties on net sales.GlobeNewswire Inc. · Jun 7, 2026

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsightThe presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.GlobeNewswire Inc. · May 11, 2026

Why Lenz Therapeutics Stock Crashed TodayLenz Therapeutics stock plummeted 11.2% after missing Q4 earnings and sales expectations. The vision drug company reported a loss of $1.16 per share on $1.6 million in sales, versus analyst forecasts of $0.90 loss on $3.1 million in sales. Despite being on pace for 45,000 VIZZ prescriptions by end of Q1 2026, weak launch quarter uptake and quadrupled SG&A expenses disappointed investors. Management's lack of forward guidance further fueled the selloff.The Motley Fool · Mar 24, 2026

Lenz (LENZ) Q2 Revenue Jumps 604%Lenz Therapeutics reported $5.0 million in Q2 2025 revenue from licensing deals, exceeding analyst expectations. The company is preparing for FDA review of LNZ100, an eye drop for presbyopia, with a decision expected by August 8, 2025. Despite increased operating expenses leading to a wider net loss, Lenz remains focused on commercial readiness.The Motley Fool · Jul 31, 2025

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024Capstone data from Phase 3 CLARITY study to be presentedGlobeNewswire Inc. · Jun 10, 2024

LENZ Therapeutics to Present at the Jefferies Global Healthcare ConferenceSAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.GlobeNewswire Inc. · May 30, 2024

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesReported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024GlobeNewswire Inc. · May 8, 2024

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update.GlobeNewswire Inc. · May 1, 2024

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst SaysLast week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101. Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity. Citi analyst writes that with promising Phase 3 ...Full story available on Benzinga.comBenzinga · Apr 10, 2024

LE

LENZLENZ Therapeutics, Inc. Common Stock

LENZ

Pay with—

Available Balance0.00

Your PositionYou don't own any LENZ yet.

Related Tickers

Earnings